United States
Patient Instruction & Fitting Guides
Consumer
Search
Product search
Practitioner home > Our Products > Product Technologies > ActivControl® Technology

ActivControl® Technology

ActivControl® Technology for slowing myopia progression in age-appropriate children.

Special contact lens technology for children that corrects their vision while slowing myopia progression in children (aged 8-12 at the initiation of treatment) by 59%, on average1.

explaining myopia

For illustrative purposes only 

Did you know? 8 in 10 eye care professionals agree that they worry about their pediatric patients having significant eye health issues, such as retinal detachment or glaucoma, later in their lives due to the progression of their myopia2. And that risk multiplies as a child’s prescriptions get stronger3.

Thanks to ActivControl® Technology, children (aged 8-12 at the initiation of treatment) can now enjoy freedom from glasses when wearing their contact lenses while potentially slowing down the progression of their myopia1*.

Benefits:

  • Specifically designed to reduce the progression of myopia (nearsightedness)1; helping to control the axial length and refractive error increases of the eye in age-appropriate children which can help to reduce the risk of myopia-related vision complications later in life4.
  • Gives age-appropriate children freedom from glasses when wearing their contact lenses1*.
  • Easy for age-appropriate children to use1. Convenient daily disposable contact lenses—no need to clean or store them.

 

 

Relevant products

Also of Interest:

Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters(spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
* Compared with a single-vision one-day lens over a three-year period.
References:

  1. Chamberlain P, et al. “A 3-year Randomized Clinical Trial of MiSight® Lenses for Myopia Control.” Optom Vis Sci 2019;96:556–567.
  2. CVI data on file 2019. Global survey by Decision Analyst with 402 ECPs in UK, Canada, Germany, Spain, Hong Kong, Australia/NZ. 82% agreed on a 1-10 point scale (top 4-box).
  3. Flitcroft DI. “The complex interactions of retinal, optical, and environmental factors in myopia.” Prog Retin Eye Res 2012;31(6):622-660.
  4. Tideman JW, Snabel MC, Tedja MS, et al. “Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia.” JAMA Ophthalmol 2016;134:1355-1363.